ClinicaliQ Trial Snapshot
- A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn’s Disease — Active Not Recruiting • Phase II • Gastroenterology • NCT05242471.
- Testing whether combining two existing Crohn's drugs works better than either drug alone at 48 weeks.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab. Conditions: Crohn's Disease Interventions: Guselkumab, Golimumab, JNJ-78934804, Placebo Lead Sponsor: Janssen Research & Development, LLC Planned Enrollment: 703 participants